CHARITY COMMISSION
FOR ENGLAND AND WALES
Independent examiner's
report on the accounts
Section A
Independent Examlner's Report
Report to the truste&sl
members of
Charity Name
Chronic Lymphocytic Leukaemia Support Association UK (CLLSA)
On accounts for the year
ended
31 De¢ember 2024
Charity no
(if any}
1178482
Set out on pages
Iremember lo include the psge nutnbers of addilion815heelsl
I report to the truslees on my examination ofthe a¢counts of the above
charity {'the Trust") for the year ended 31112124.
Responsibilities and As the charity truslees of the Trust, you are responsible for the preparation
basis of report of the accounts in accordance with the requirements of the Charities Act
2011 flhe Act").
I report in respect of my examination of the Trust's accounts carried out
und&r section 145 of the 2011 Act and in carrying out my examination, I
have followed the applicable Directions given by the Charity Commission
under seGlion 145(5){bl of the Act.
I have completed my examination. I confirm that no material matters have
come to my attention {other than that disclosed below ') in connection with
the examination which gives me cause to believe that in, any material
respect-
accounting records were not kept in accordance with seotion 130 of
the Act or
the accounts do nol accord with the accounting records
Independent
examiner's statement
I have no concerns and have come across no other matters in connection
with the examination to which attention should be drawn in order to enable a
proper understanding of the accounts lo be reached.
Please delete Ihe words in the brackets if they do not apply.
Slgned:
Date:
Name:
Andy Davis FCA
Relevant professional
quallficatlonls) or body
(If any):
Institute of Chartered Accountants in England and Wales {ICAEW)
Address:
The Old Post Office, 41-43 Market Place
Chippenham
SN15 3HR
IER
October 2018

Section B
Disclosure
Only complete if the examiner needs to highlight matlers of concern (see CC32.
Independent examination of charity accounts.. directions and guidance for
examiners).
Give here brief details of
any items that the
examiner wishes to
disclose.
IER
Octobor 2018

CHARITY COMMISSION
FOR ENGtAND AND WALES
Chronlc LymphoGyll¢ Leukagmts Support ￿550C￿lIon U
1178482
Receipts and payments accounts
CC16a
For thè p•rlod
from
01110rI023
3111V2024
Section A Receipts and payments
Unre5trfcted
fund•
tOlh• n•aig11
ReslriGted
fund•
Endowment
funds
Total fund*
La¥tyear
toth• nwi•¥t£
toth•n•arttt£
10 lh• n•ir••t£
toth• nMMtstÉ
Al Rè¢èl t$
138.12Y
IJO 127
Grenlg
928
2.194
4#2
6.926
Bonk •nd d• ftlnt¢re•t
Sub total{Gmss Incom8 ftsr
AR)
180,140
116M47
A2 A8S•t and Inve¥tment sAIo•,
(#•• table
931
931
Sub total
•Ji
931
16t.771
80,000
221.yll
116,047
A3Pa
ments
SupportwJFk
Adm5nhlièLk)n
FundtaWng
69,667
112.637
37,115
17.856
Sub lolal
151.105
¢o.ooo
211.15$
166,30B
A4 A•8•t and Invostmant
49.367
Sub totsl
49.367
Toial payments
1151,111J
60,000
211.1
217.676
Net of recelptsl{paymontsJ
A5 Tran•l•rs b•lwo•n fund•
A6 Ca¥h fund¥ last ygar •nd
Cash funds th18 yèarond
10.618
10.616
101,628
278,86T
287A83
278,867
287,4eJ
378,496
276,867
CCXX R1 at¢ounls (88)
07105R025

Seclion B Stalemenl ol assets and liabililies at the end ot Ihe period
H•stiielgd
lynd$
19 n••rts1 £
Gnoowmont
funds
lunds
B1 Cash lund
Bankéi¢
2IS.B1S
tyotsnniin'i
IA70
Tolal casl? lundj
207.489
&.t41*Thb'.
Unigslrletèd
Iynd?
£nilowmot)I
tund
1¢ nv•*éal t
lund$
io n?•rÈsi t
B2 Other monetttry ossets
920
>ffTh)Id trxpMr.r.'.
625
10 whlt
as*ttl bolon
Co$i1¢gll•na
B3 Inveslmenl 3988ts
FuDdto whlch
•*•ei b•iDn
Coll iopllonpl)
-loLllontsiL_
B4 Assèts rfrtalnèd IOT the
eharlly s own use
Fufid lo whlth
Whvn duo
lopI￿n￿lI
BS Llabllltlets
Pfiiil
Daio o.
approval
PE<60
i>/h /2)-1
c.xx H? AC{.'IIUll.'s ISS..

CHARITY COMMISSION
FOR ENGLAND AND WALES
Tru¥t9e$' annual report Ilncludlng DlreGto.rs' reportl
forthe perlod from: 01 October 2023 to: 31 December 2024
Charlty name: Chronlc Lymphoeytlc Leukaemla Support Assoclatlon UK (CLLSA)
Charlty reglstratlon number: 1178482
Objectlves and actlvlties
SORP réferènca
Pa(a 1.17
Summary of Ihe purp08es of th8
charity as 881 oul in ils
governing document
1. To r91ieve ?lthne66 and lo pT¢serve and
protect health by providing support to chronic
tymphocytic18uka8mla (CLLI p2118nl8 and thelr
ttArér8. ICLL inclurtas similar f8laled condition5
such as SLL).
2. To advanc& publlc educallon In CLL related
matlors primarily in the UK thiough publi¢ation5
and Ihe inlernel.
3. To promo1& and oupport scienlrfiG resoarth
into the Ifealm8nt and car8 of all CLL patients.
Summaiy of Ihe main aclivilie$
in relation lo those Pufptrses for
thè public b8n8fil, in partieJJlar.
the activili&s, proje¢l8 or
services idenlrfied in the
accounts.
Pgra 1.17 and
1.19
1. The provision ol up to date and 8ccessibl&
information about CLL, thè rangè of treatments
currèntly 8vailablo and the lal&81 r9s8arch into
the cafe and Ire8lm9nl of CLL, through the
Charity's websila, webinar8, member
conferences, publl¢albns and 4 telephone
hglplin8.
2. The d&velopment of opportunities lo share
underslandlnu and personal experience by
bringing CLL palienls logelher. and by crealing
mutual support groups and ne￿rks.
3. Acllng as a vol¢e for CLL patients.
representing Ihelr Interests wilh the
pharmar£ullcal Industry, cllnlclans, NHS, cancer
cmre pollcy and drug regulatory aulharille5,
funding and COEnmissioning groups and
Govemmenl.
4. Th8 promollon ofan awareness of CLLSA,
together with ils role amongst health care
providers and decision makers, provideis of non-
healthcarè PTodutttS and Sérvicès. olher blood
cancer patient groups and Iho wider wblic.

81818m8nt confim)ing wh&thar
thè Irusle&s havé had règard lo
th8 guidanrA issued by the
Charity Commisslon on publi¢
b&nefil
PaT8 I.q8
In undertaking Ihfrso aclivilies. lh8 Trus18es
c￿nfIrM that Ihgy have had ¥egard to the
guidance issued by th6 Charity Commission on
th9 mall8r of publ{¢ banelil.
Addltlonal Information loptlonal)
You may choose to Include further sialomonls where relevant aboul..
SORP i•f¢rgnGg
Para 1.38
Pollcy on grant making
Policy on sts¢ial investment
Including progr8rn related
invoslmgnl
Para 1.38
Contribulion made by
volunleors
Para 1.3B
Other
Achlevements and performance
Summaryofthe main
achievements of th8 charity,
Idenlifying the difference Ihg
charrty's work has mada lo the
ircumsl8nces ol ils
beneficiaries and any wid8r
beneli15 to socigly as a whole.
Para 1.20
Every mèmbor of the Board of Trustees ha5 bgon
ffèelÉd personally by CLL, 8iiher as a pallanl or
Ihrouoh a close personal rélationship with
patient, and ac¢or(Jingly is w811 ploced to judge
the nèeds ¢f GLL pgtienls and Ihelr supporte
With the assislanc￿ of d8dlealed part Ilme
members Of staff, gvery individual Trustee is I￿th
directly and heavily involved in the delivery of Ih
support services that the Charlly has lo.offer.
As11 h8s moved on Irom Ihe Immediate
ehalleng8s of Ihe Covld.19 pandemlc. the Charfty
has..
1. ReinlroduGed In-person member conf8fence8
as well as continuing lo provldo onlin8 webinar
piesenlalions. Th&s8 presenlalions conlinu8d
lo be fronted by many of the legding expèrts in
the field of the Ifealmenl of CLL.
2. Continued 118 ¢106e ¢ollaboralion wila th$ UK
CLL Forum. thus helping th8 Forum lo brid9a
th9 gap ba￿￿en Scientists. Clinicians and
Palients.
3. Continugd ils work with the Blood Can¢er
Allianc8 and with Cfjn¢er52 lo promole lh8
Interests of Ihoso sufferir*J from blood cancers
8nor81, and from CLL In
8rtlculor.

4. Conlinuod with the development and roll out of
ils Support ACT PTogramme, offering us8rs
access to guidanog and support lo help
improvo the well-being of CLL pallenls and
their immediatè supportors.
S. Conlinuod lo mainl8in a lel8phon8 h8lplinè
sérvice that is available to offer Immediate
Support and ouid8ncg 10 CLL palien18 and the
5UPPOrters,
6. Conllnued lo partlclp818 in p&thering
arrangements wilh major pharmaceutical
ompanie5 designed lo offer those compani88
kèy inslghls Into the way In whlch Irealmenls
for CLL impact on the lives and wellbefng of
patients.
7. Continued lo benefit from donations and
fundralslng aclivilie3 that were underlaken by
its supporters. 2024 was the 20th Anniversary
of CLL Support and our Challeng8 20
encouraged members lo undortake activiliès
8nd raiso furKfs for th9 Charily
8. Continued 10 benafil from fvnding provlded by
th8 pharmacautiC81 inthsty.
Additional Infomiation (optionall
You may choos8 to in¢lud$ further Slalgments where rebvant aboul..
Achi8V8menl8 against
objectlves gel
Para 1.41
Perforrnance ol fundrai8lng
aclivltigs auainst objgGtives sel
P8r4 1.41

Invgslment performance agalnsl
objectives
Para q.41
Olher

Flnancial review
Revlew of thè charit￿S financial
position at the end ol the pgrlod
P8f8 1.21
Statement explaining the policy
for holding reservès Staling why
they are hèld
Para 1.22
Thè Charity aims lo maintain total reserv¢s Ihal
are no more than 18 months ol Ihe anlicipaled
normal18vel of amual runnlno cosl8.
An amount which is between 12 and 15 month5,
planned expendllure Is held In the fom of c8sh
rese￿eS to en8uie both conliryjèd finanttial
58curily and to provtde lor conliryenci8B.
In delemiining these flgure8, Ihg Trustee¥ have
con8idereiS thè need lo hold back some funds as
résoNe$, using th8 categories 881 out In the
Charily Commission Guidanc£ Ooeumenl CC19'.
Charity reserves.- l)ulldlng reslli8nce.
Amounl of reserves held
Para 1.22
At lh6 end of th& period the Charily held r¢serve8
01 £342,001
Raasons for holdlng zero
reserves
Para 1.22
NIA
Delalls of fund mèlerially in
doficil
Paia 1.24
Noné
Explanalic)n ol any uncertainties
about Ihe charily CA)nlinuing as
a golng concern
Pjra 1.23
None Ir) the immediately foroseaable future
Addltlonal Infomiatlon loptlonal)
You may ¢hoo89 to include further sts19mgnl$ where Televanl about..
The ch8rily's principal sourc9$
of fund8 (Indudln9 ariy
fundraigingl
Para 1.47
Investmant policy Bnd
obleGlives including any social
Inveslmenl policy adoptèd
Para 1.46
A descriplion of the principal
risks facing the charity
Para 1.46
Other
Structure, governanco and management
D8Bcriplion of charity'$ Irusls:
Type of governing doGument'.
Para 1.25
Tru81 De6d dated 22tvJ May 2018
How 18 the charily conslrtul8d?
Para 1.25
Chafilable Incorporated Organi8alion

Trustee selgction melho
includino del8ils of any
cKnslilulional provision$
Para 1.25
Eleclion by a majorily ol the 8xisling Trus18ès
Addluonal Infomiatlon (optlonall
You may choose to Inolude furlher slalemenl8 %there relevant about..
PoliGies 2nd proGedure5
aijopled for the Inductlon and
training of Iru51ees
Para 1.51
Th8 charily's organisalional
slfuolure and any wider nelwork
wilh which Ihe charily works
Para 1.51
Relationship with any relaled
P8rtièS
Para 1.51
Other
Reference and admlnlstratlve detalls
Charity name
Chronlc Lymphocytlo Leukaomla Support AB60Glatlon UK
{CLLSAI
Other nam8 th8 charity us88
{1) CLL Support
1111 CLL Support As60clatlon
Reglstered ch8rity number
1178482
Chadly's prlnclpal address
Su5te 112- 8 The Brldge, Chlppenham. Wllt8. SN16 1FY
Name8 of the Gharlty tru$t9e8 who manage tho charlty
Name ofpèrson lor
body) •ntllèd to appolnt
tru8tee
Ifan
TNsts• nam•
Offloo111 any)
DateB acted If not for whole year
Allen, Poler
G8rdom, Brlan
Granl, Norah
Greensmyth, John
Holland, Anthèa
Linds£y, Hilary
Mercer, Frank
10.06.2024 to 31.12.2024
01.10.202310 18.10.2023
Chair
Treasurer to 16.10.
2023
01.10.2023 to 16.10.2023
Wiegman, Gail
steffi Sutters
Debra Yales
01.10.2023 to 19.02.2024
10
11
Steven Abraham8
01.10.202310 19.08.2024

12
Andrew Taylor
Trea8ur8r from
16.10.2023
01.10.2023 to 29.11.2024
Cor
orate Irustees- names of the directors at the date the re
Dlrector name
rtwasa
roved
NIA
Name of tTUStees holding title to properly belonging to the charily
Tnjstee name
Daté8 4et•d if not for wholo
NIA
Funds held as custodian trustees on behalf of others
Descfiplion of the assets held In
this Capa￿tY
Nono
Name and objects of th& charily
on whose behalf Ihe assèts are
hold and how this falls within
the custodian charily's oble¢ts
NIA
D8t2ils of arrangements for safe
¢ustody and segiegalion (Jr
such as8$ls from Ihe charit￿$
own assets
NIA
Addltsonal infomiation loptionall
Namgs and addfessos of adv15er8 (opuonal Infomiatlon)
of advlser
Name
Addr86S
Name of chlof •x•cutlve or names of senlor Staff members {optlonal Informatlon)
Exemptions from disclosure
Reason for non-disclo$ur8 of key p&rsonnel details
Declaratlons

abtsv
Th•lrn•t•M d*0 Ihal th•y hw• approv￿ th• tru•tO••' f•PDrt Ilndudlnq dlrnvtw•' r•port)
on b•hAII •1 lh• ob•Oty* Inj•1•￿A]rO
8lgnAtur•(8)
Full namo(81
Po•ltlon
Hllary Lindsay
PeterAllon
Chelr of TN8tge8
Tru#tee